Month: July 2015

“Endometrial Cancer – Pipeline Insights, 2015”- A DelveInsight’s Report

DelveInsight Leave a comment

DelveInsight, the leading market research and consulting company has added a new report “Endometrial Cancer – Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date information of market till the date of order.

The Endometrial Cancer – Pipeline Insights, 2015 report provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions.

Untitled

Key Highlights of the Report:

  • The report gives information of 35+ pipeline drugs with 30+ companies actively involved in drug development. There are 7 drugs which are in pre-clinical phase, 10 in phase I, 8 in phase I/II and 11 in phase II.
  • Aeterna Zentaris is developing a lead product Zoptarelin doxorubicin which is in Phase III.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
  • Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Endometrial Cancer-Pipeline Insights, 2015 report provides Endometrial Cancer Landscape across the globe. Therefore the report on Endometrial Cancer-Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 – A DelveInsight Report

DelveInsight Leave a comment

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback from clients.

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.

1067742_deactivated-tcell-pd1-pdl1-14

Key Highlights of the Report:

  • Overview of PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA) and biomarkers of PD-1 and PD-L1 inhibitors Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented in to major geographies
  • Report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry and impact on market after expiry and detail profiling of Pipeline assets
  • Key topics covered include strategic competitor assessment, market characterization, opportunities, barriers and challenges in the market along with SWOT analysis of the PD-1 and PD-L1 inhibitors market
  • Pipeline analysis: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates
  • Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of market with upcoming blockbuster molecules and their impact on overall market.

According to the analysis, 34 drugs* are in pipeline. Out of 34, 22* are in combination development with other therapeutics agentspD1Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. The market for PD-1 and PD-L1 drugs might be billions of dollars richer than many believe. These drugs which include Bristol-Myers’ Opdivo and Merck’s Keytruda, are going to be Blockbuster in upcoming years.

Untitled

Delveinsight report on PD-1 and PD-L1 help companies in understanding Oncology market dynamics and therefore giving opportunities for strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition, reports will assuage companies to detect specific tumors, determine genetic predisposition and biological response to cancer therapy.

DelveInsight is offering the Report at a price of USD 2,950 as a single user license, USD 5,900 as a site license and USD 8,850 as a Global/Enterprise License.

For more information mail us at info@delveinsight.com

About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

DelveInsight Leave a comment

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA.

It is an autoimmune disorder when body’s own immune cell starts attacking healthy cells. This results in inflammation. It is also known as “systemic onset juvenile rheumatoid arthritis”It makes the joints inflamed and stiff for more than six weeks.

DelveInsight report on Systemic Juvenile Idiopathic Arthritis provides comparative study of drugs under development. The report provides assessment of Tofacitinib pipeline drug by Pfizer Phase III. In addition to this, the report imparts information on several other drugs as well.

Key Highlights of Report:

  • Comprehensive insights about pipeline drugs across this indication
  • Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages
  • Therapeutics assessment by monotherapy and combination products and molecule type drug information
  • Companies involved in therapeutic development of the products
  • Discontinued and dormant products

DelveInsight is offering the Report at a price of US 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

.

Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015

DelveInsight Leave a comment

DelveInsight, the leading market research and consulting company has added new report  Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date information of market till the date order has been placed.

This Indication pipeline Insight Report provides client with details on Bile Duct Cancer (Cholangiocarcinoma) drugs across the globe. It comprehensively includes:

  • The report imparts information of 30+ pipeline drugs along with 25+ active company names, among which 14 drugs are in phase II, 10 in phase I, 2 in pre – clinical and 1 in discovery phase.
  • Assessment of Porfimer Sodium pipeline drug in Phase III stage under development by Concordia Healthcare.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.Bile Duct Cancer

Bile Duct Cancer Cholangiocarcinoma) Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

DelveInsight is offering the Report at a price of US 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Oral Mucositis-Pipeline Insights, 2015- A DelveInsight Report

DelveInsight Leave a comment

In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of developing oral mucositis with mean incidence of 80-100%.

It is estimated that 89.0%-100.0% of the population undergoing head and neck chemotherapy will develop oral mucositis. In addition there are >4M stage 3-4 cancer patients worldwide (>1m in U.S.) that are receiving high doses of CT or a combination of CT/RT that develop OM 1.0%-53.0% of the time.

The current status of Oral mucositis (OM) treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and palifermin, and a growth factor. None of these products have been completely successful in treating OM and a high unmet medical need exists.

DelveInsight report on Oral Mucositis gives comparative study of drugs under development. The report provides assessment of AG-013 pipeline drug by ActogeniX NV (Intrexon) which is in Phase II/III. In addition to this, the report imparts information on several other drugs as well, among which 6 are in phase II, 3 in phase I, 3 in pre – clinical and 1 in discovery phase.

hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt

Key highlights of the report

  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

The Oral Mucositis-Pipeline Insights, 2015 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Oral Mucositis-Pipeline Insights helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Oral Mucositis-Pipeline Insight Report, email at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) – Competitive Landscape, Pipeline and Market Analysis, 2015

DelveInsight Leave a comment

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T –cells and is continuously involved in the inhibitory T-cell responses.CTLA-4  (Cytotoxic T-lymphocyte-associated protein 4), also known as CD152  is a protein receptor that down regulates the immune system by consistently affecting the T cell responses. It is generally encoded by CTLA-4 gene in humans.

Untitled

The current Oncology market is steered by Bristol Myers Squibb with Yervoy (monoclonal antibody) approved for melanoma. The annual sales for Yervoy have increased by 23% in US and 56% in Non-US cities in 2014 as compared to 2013.

gfxhyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy

Several other companies are actively working which includes Astrazeneca, Merck, Roche & Pfizer. There are several drugs under pipeline among which Tremelimumab had shown inordinate results in clinical studies for treating malignant mesothelioma.

DelveInsight’s, Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) – Competitive Landscape, Pipeline and Market Analysis, 2015 provides the in-depth analysis of the pipeline assets across Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) targets & inhibitors. The prime foucs of this report is to track competitor pipeline molecules, related research activities, t, collaborations, in-licensing and out-licensing deals. Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) – Competitive Landscape, Pipeline and Market Analysis, 2015 Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to optimize portfolios and to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1450 as a single user license, USD 2900 as a site license and USD 4000 as a Global/Enterprise License.

For more information on our Oncology Reports email us at info@delveInsight.com

About:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight’s Oncology based Reports, 2015

DelveInsight Leave a comment
DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is placed.
Limited alternatives and high unmet needs have made global cancer market to rise unexpectedly and is presumed to reach around $ 100-110 billion by 2020. Recently companies have come up with new targeted therapies involving Immunotherapy. It is a major technological breakthrough in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease which are expected to deliver improved results in terms of safety and efficacy.

The current Oncology market is steered by companies such as Roche for Avastin, Herceptin & Rituxan, Novartis for Gleevac/Glivec and Celgene for Revlimid.fgrfyhtgfjcyuhik ju8o vcccccccccccccccccc

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight’s Reports on gene therapy, PD-1/PDL-1, Antibody-Drug Conjugate (ADC) & CAR-T provides assessment over advancement in technologies, market trend, partnering & licensing opportunities, pipeline scenario and competitive landscape. In addition, the Oncology Reports will help to identify the key players of market and the potential market movers and barriers. After getting great response and feedback now we are planning to launch reports on Stem Cell Oncology, Bruton’s Tyrosine Kinase (BTK) Inhibitors, TIM3, OX40, and LAG3.

DelveInsight’s Oncology reports help companies in understanding Oncology market dynamics and therefore giving opportunities for strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition, reports will assuage companies to detect specific tumors, determine genetic predisposition and biological response to cancer therapy.

For more information on our Oncology Reports email us at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Website Link: http://delveinsight.com/

DelveInsight’s Indication Active Pharmaceutical Ingredient (API) Reports– 2015

DelveInsight Leave a comment

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports

Indication-API Insights

DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic area such as Oncology, Cardiovascular disease, and Autoimmune disorders and Infectious disease.

DelveInsight’s Indication API insight report provides global competitive and therapeutic assessment on marketed drugs, API manufacturers, patent expiration and exclusivity. The report gives clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries. These Reports gives complete information on marketed drugs along with Global API Manufacturers and regulatory filings across Europe, US, India and China. It gives information of global Market therapeutics scenario, regulatory information, marketing status and detail of product profiles for marketed products with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical description. The Report also provides Global drug sales forecast up to 2016.

The Reports give opportunities to generic manufacturers and also helps API industry to track closest competitors and prioritizing new drug intermediates to add to the portfolio when drug goes off patent. The Indication API insight report helps to identify the strategic drivers and market opportunities.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on API insight Reports, email at info@delveInsight.com

About us

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Website Link: http://delveinsight.com/